Rapcabtagene autoleucel shows frontline promise for high-risk LBCL
Early findings show rapcabtagene autoleucel could be a first-line treatment for patients with high-risk LBCL.
Bispecific, fresh formula CAR-T superior to R-GEMOx in LBCL
Zamto-cel shows survival benefits over R-GEMOx in patients with R/R LBCL who are ineligible for transplant.
Consistent high response with the bispecific prizlo-cel in R/R LBCL
Prizlo-cel maintains high complete response rates in patients with R/R LBCL in a study looking at the potential effects of correlated biomarkers.
Synergistic CAR-T targeting with rapid manufacturing shows LBCL benefits
Support for further development of KITE-753 for relapsed/refractory large B-cell lymphoma after findings suggest a rapid and strong response.
Bi-specific CAR-T cell therapy shows promise for R/R LBCL
Early support for further development of dual CD19 and CD20 targeting in CAR-T cell treatment for patients with relapsed/refractory large-B cell lymphoma.
IL-15 polymer conjugate enhances liso-cel response in R/R LBCL
Promising CAR-T cell expansion and persistence with the addition of NKTR-255 to lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Fast production, low high-grade toxicity with CAR-T cell therapy in R/R NHL
ATALANTA-1 study shows a manageable safety profile for the CAR T-cell therapy GLPG5101 for patients with relapsed/refractory non-Hodgkin lymphoma
‘High response rates’ with rapcabtagene autoleucel in R/R DLBCL
The CAR-T cell therapy rapcabtagene autoleucel shows high and durable complete response rates in patients with relapsed/refractory DLBCL.
